Trials / Conditions / Refractory Leukemia

Refractory Leukemia

23 registered clinical trials studyying Refractory Leukemia — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leu NCT07439211	Jacqueline Garcia, MD	Phase 1
Recruiting	A Study of Revumenib and Mezigdomide in People With Leukemia NCT07356154	Memorial Sloan Kettering Cancer Center	Phase 1 / Phase 2
Recruiting	Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia NCT07297173	Beijing 302 Hospital	Phase 1
Recruiting	Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) NCT06644183	Jennifer R. Brown, MD, PhD	Phase 1 / Phase 2
Withdrawn	Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory L NCT05321940	Juan C. Ramos, MD	Phase 1
Recruiting	Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmac NCT06006403	Chongqing Precision Biotech Co., Ltd	Phase 1 / Phase 2
Recruiting	Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia NCT05870995	Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia NCT05576532	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemi NCT05519384	Institute of Hematology & Blood Diseases Hospital, China	EARLY_Phase 1
Unknown	Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph NCT05495035	Institute of Hematology & Blood Diseases Hospital, China	Phase 1
Recruiting	Solving Riddles Through Sequencing NCT05046444	Munich Leukemia Laboratory	—
Recruiting	Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML NCT05305859	The First Affiliated Hospital of Xiamen University	Phase 2
Active Not Recruiting	Tegavivint for the Treatment of Relapsed or Refractory Leukemia NCT04874480	M.D. Anderson Cancer Center	Phase 1
Recruiting	CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic NCT05043571	National University Hospital, Singapore	Phase 1
Unknown	PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AM NCT04722952	The First Affiliated Hospital of Soochow University	Phase 3
Unknown	Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies NCT04684472	Liqun Zou	Phase 1
Unknown	Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT05164042	Shenzhen University General Hospital	Phase 1 / Phase 2
Completed	Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospita NCT04597086	Ohio State University Comprehensive Cancer Center	N/A
Recruiting	Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clin NCT04282811	Gruppo Italiano Malattie EMatologiche dell'Adulto	—
Unknown	Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Hae NCT04470947	Medical University of Vienna	—
Unknown	Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia NCT03799224	Peking University People's Hospital	Phase 2 / Phase 3
Completed	Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children NCT02512926	Stanford University	Phase 1
Completed	Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenou NCT00880269	Novartis Pharmaceuticals	Phase 2